This technology is a graphene-based nanosensor that can be used to monitor target insulin levels in real time.
There are currently no commercially available products that allow patients with type I diabetes to directly measure their own insulin levels. Instead, they must rely on blood glucose measurements to determine when insulin injections are needed. Current approaches for monitoring insulin levels are time-consuming, require offline detection, or have low sensitivity. Since type I diabetes patients have time-varying insulin levels, an approach that could enable rapid and accurate insulin monitoring would be highly beneficial.
This graphene nanosensor is based on a field-effect transistor that uses highly sensitive nucleic acid aptamers to bind to a target analyte, which in turn causes a detectable change in the electrical properties of the graphene. The device is ten times more sensitive than currently available insulin-sensing technologies, enabling selective, real-time detection of insulin at concentrations as low as 1 nM. Thus, this technology has the potential to significantly improve the state of type I diabetes management. Additionally, this device can measure other characteristics of blood and body fluids such as gas concentration and pH.
The graphene nanosensor has been tested and demonstrated high performance while monitoring insulin concentrations between 1 nM and 500 nM.
IR CU17297
Licensing Contact: Dovina Qu